Scope and claims analysis and US patent landscape for U.S. Patent 9,572,797 (bendamustine liquid, PG-ester-limited, antioxidant-stabilized non-aqueous formulations and leukemia/Hodgkin’s/multiple myeloma treatment methods)
U.S. Patent 9,572,797 is claim-centered on a narrow formulation-performance axis: a liquid, non-aqueous bendamustine composition with specific propylene glycol/PEG ratios and an antioxidant package, constrained by “total PG esters” impurity limits at defined storage times/temperatures, used to treat leukemia, Hodgkin’s disease, or multiple myeloma. The independent method claim (and dependent claims) create a direct infringement hook for drug products that match the formulation parameters and meet the storage/impurity thresholds. The practical enforcement risk is driven less by the therapeutic indication and more by whether an accused product’s composition (solvent system, antioxidant selection/amount, and benzene-free antioxidant class) reproduces the “total PG esters” performance profile.
What is U.S. Patent 9,572,797 claiming for bendamustine in non-aqueous propylene glycol/PEG liquid formulations?
Direct answer (claim core): The patent claims methods of treating leukemia, Hodgkin’s disease, or multiple myeloma using a liquid bendamustine composition comprising bendamustine + non-aqueous fluid with 5–10% total volume of a PG/PEG antioxidant-containing solvent system, constrained by total PG ester levels at specific storage conditions, with defined PEG:PG ratios.
Key claim elements (common to Claim 1 and Claim 16)
Below is the “checklist” embedded in Claim 1 (and repeated in Claim 16 with the 15 days / 25°C threshold):
-
Active: bendamustine (or a pharmaceutically acceptable salt).
-
Dosage form / vehicle: liquid bendamustine-containing composition, non-aqueous pharmaceutically acceptable fluid.
-
Solvent system proportions:
- total solvent fluid comprises about 5% to about 10% (v/v) of the pharmaceutically acceptable fluid containing:
- propylene glycol (PG)
- polyethylene glycol (PEG)
-
PEG:PG ratio options (defined set):
- about 95:5
- about 90:10
- about 85:15
- about 80:20
- about 75:25
-
Antioxidant package: stabilizing amount of one selected from:
- thioglycerol
- monothioglycerol
- lipoic acid
- propyl gallate
- methionine
- cysteine
- metabisulfites
- sodium formaldehyde sulfoxylate
- phenol-containing aromatic and aliphatic compounds
- dihydrolipoic acid
-
Impurity/performance constraint: total PG esters limited at defined storage conditions.
- Claim 1 uses ≤0.11% total PG esters at about 1 month at about 5°C.
- Claim 16 uses ≤0.12% total PG esters at about 15 days at about 25°C.
-
Treatment scope: methods for leukemia, Hodgkin’s disease, or multiple myeloma in a mammal.
Independent claims as “formulation-with-performance” enforcement targets
Claim 1 (structure):
Method of treating leukemia/Hodgkin’s/multiple myeloma by administering a liquid bendamustine composition with:
- solvent system: 5–10% non-aqueous fluid of PG + PEG
- antioxidant selection from the enumerated group
- impurity: ≤0.11% total PG esters at ~1 month, ~5°C
- PEG:PG ratio limited to the listed set
Claim 16 (structure):
Method of treating leukemia/Hodgkin’s/multiple myeloma by administering a similar liquid bendamustine composition with:
- impurity: ≤0.12% total PG esters at ~15 days, ~25°C
- PEG:PG ratio limited to the same set
- antioxidant from the same enumerated group
This duality matters in litigation: an accused product can potentially avoid one threshold while still meeting the other, but infringement risk remains if any independent claim is met by matching thresholds and formulation parameters.
How do the dependent claims narrow U.S. 9,572,797’s scope (PG esters, storage time, temperatures, concentrations, and antioxidants)?
Dependent claims extend claim coverage into specific manufacturing “settings” and acceptance limits. The narrower the impurity/time window, the more product-specific the infringement analysis becomes.
PG ester impurity ceilings by storage condition
The claims recite multiple “acceptance limit” points. The most directly relevant for freedom-to-operate and design-around is that “total PG esters” is controlled at different times and temperatures.
- Claim 2: ≤0.18% total PG esters at ~12 months at ~5°C
- Claim 7: ≤0.12% total PG esters at ~15 days at ~25°C
- Claim 8: ≤0.25% total PG esters at ~1 month at ~25°C
- Claim 9: ≤0.43% total PG esters at ~3 months at ~25°C
- Claim 10: ≤0.77% total PG esters at ~6 months at ~25°C
- Claim 20: a “stacked” combination at 25°C:
- ≤0.25% at ~1 month
- ≤0.43% at ~3 months
- ≤0.77% at ~6 months
Practical scope effect: If an accused product’s stability profile yields higher PG ester formation at these timepoints, it may defeat infringement of those dependent claims. But infringement of independent claims still remains if the asserted independent claim’s specific threshold is met.
Propylene glycol level specificity
- Claim 3: propylene glycol in fluid is ~10%
- Claim 21 (dependent on Claim 16): propylene glycol in fluid is ~10%
Practical scope effect: Matching the “ratio set” alone may not suffice for products with different PG:PEG ratios that do not correspond to PG ~10% (depending on how the “about 10%” is interpreted in the overall non-aqueous fluid volume vs PG proportion within the solvent system). The claims create a direct target for products aligned to PG ~10%.
Bendamustine concentration bands
- Claim 4: bendamustine concentration ~20 mg/mL to ~60 mg/mL
- Claim 5: bendamustine concentration ~25 mg/mL to ~50 mg/mL
- Claim 6: bendamustine concentration ~50 mg/mL
- Claim 22: (dependent on Claim 16): same ~20 to ~60 mg/mL
- Claim 23: (dependent on Claim 16): ~25 to ~50 mg/mL
- Claim 24: (dependent on Claim 16): ~50 mg/mL
Practical scope effect: If an accused liquid is outside these concentration bands, it can fall outside dependent claim coverage. But it may still infringe if the independent claim does not require concentration bands beyond “liquid bendamustine-containing composition.” In your provided claim text, concentration limits appear in dependent claims only.
Antioxidant narrowing
- Claim 11: antioxidant is thioglycerol or monothioglycerol
- Claim 12: antioxidant concentration ~2.5 mg/mL to ~35 mg/mL
Practical scope effect: If the antioxidant is outside the enumerated list, it avoids the claimed stabilization package. If it is within the list but outside the concentration band, it may avoid the specific antioxidant concentration dependent claims while still potentially meeting independent claim “stabilizing amount” if courts interpret “stabilizing amount” broadly.
What is the legal “shape” of U.S. 9,572,797 (method-of-use vs composition-by-structure-and-performance)?
Answer: The patent is drafted as method-of-use claims tethered to a specific composition with specific composition parameters and stability-derived impurity thresholds. The composition is not claimed as a standalone product claim in the text you provided, but infringement still turns on the composition administered.
Infringement mapping: what must be proven
For a method claim, the plaintiff typically must show:
- the accused product contains bendamustine in the claimed non-aqueous PG/PEG fluid system with antioxidant selection; and
- the accused product, as formulated and stored, meets the “total PG esters” thresholds at the claimed storage conditions; and
- the accused product is administered for leukemia, Hodgkin’s disease, or multiple myeloma.
The “total PG esters” requirement is the most litigation-sensitive element because it is inherently analytical and performance-based.
Design-around pressure points
A competing entrant seeking non-infringing product design can target at least three technical variables anchored in the claims:
- Change the solvent system so the PG:PEG ratios fall outside the listed set or total fluid v/v is outside 5–10%.
- Change antioxidant identity so it is not within the enumerated antioxidant list.
- Alter formulation/stability so total PG ester formation exceeds the claimed thresholds at the specified storage conditions.
What is the US patent landscape for bendamustine liquid formulations stabilized by antioxidants and limited “PG esters”?
Answer: The patent landscape for this niche splits into at least four clusters: (1) bendamustine liquid/solvent vehicle formulations, (2) antioxidant-stabilized bendamustine solutions, (3) impurity/stability control linked to propylene glycol ester formation, and (4) method-of-use claims tied to the stabilized liquid.
Your provided claim text alone does not include patent bibliographic identifiers (assignee, filing date, family members, continuation status, claim-set numbering, or prosecution history). Without those, an accurate “landscape” with specific neighboring US/EP/WO application numbers and expiration dates cannot be produced.
When does U.S. 9,572,797 lose exclusivity in the US (expiration and patent term drivers)?
Answer: Cannot be determined from the claim text provided. US patent term depends on filing date, priority chain, PTA, and possible terminal disclaimer or adjustment.
What Orange Book status applies to a method-of-use patent like U.S. 9,572,797?
Answer: Method-of-use patents are commonly listed in FDA Orange Book when tied to approved drugs, but whether U.S. 9,572,797 is listed (and for which NDA/BLA, strength, dosage form) is not knowable from the claim text provided.
Which generic or biosimilar entry risks exist under the claim scope of U.S. 9,572,797?
Generic small-molecule risk (most relevant)
For a generic of a liquid bendamustine product, Paragraph IV risk rises if the generic:
- uses the same or equivalent non-aqueous PG/PEG + antioxidant system; and
- achieves total PG ester limits consistent with the claimed stability/timepoints; and
- is labeled/used for the same indications.
The “total PG esters” requirement gives a measurable test for bioequivalence-adjacent product performance.
Switching or avoiding risks
- If a generic changes solvent system to avoid the PG:PEG ratio set or total v/v range, it can move outside the independent claims’ formulation limitations.
- If it uses an antioxidant not on the enumerated list, it avoids claimed antioxidant selection.
- If it accepts higher PG ester formation beyond claimed thresholds, it can defeat the “less than or equal” limitations.
How strong is U.S. 9,572,797’s enforceability based on claim specificity (what is easiest to prove vs hardest)?
Easiest to prove (typically):
- Presence of bendamustine (standard analytical confirmation).
- Solvent composition parameters (PG/PEG identity and ratio).
- Antioxidant selection if it is one of the enumerated species.
- Total PG ester quantification via validated stability/impurity methods.
Hardest to prove:
- Treatment “infringement nexus” if an accused product’s label and physician use patterns diverge from the claimed indications.
- “Stabilizing amount” interpretation for antioxidants that are present but at levels argued to be below stabilization or within a narrow boundary.
Overall, strength hinges on the enforceability of analytical performance thresholds (total PG esters) and how courts interpret “about” ranges and storage conditions.
How do Claim 1 and Claim 16 compare (threshold/timepoint differences) and what does that mean for accused product testing strategy?
Answer: They anchor infringement to different stability windows and temperatures.
- Claim 1: total PG esters ≤0.11% at ~1 month, ~5°C.
- Claim 16: total PG esters ≤0.12% at ~15 days, ~25°C.
Testing strategy implication: If litigation targets one independent claim, the evidentiary testing will focus on the relevant storage condition/timepoint. A product can theoretically meet one threshold but fail the other, which affects claim-by-claim infringement.
Key Takeaways
- U.S. 9,572,797 is a method-of-use patent that is tightly tethered to a specific liquid bendamustine formulation: non-aqueous PG/PEG solvent system at 5–10% v/v with enumerated PEG:PG ratios, and an enumerated antioxidant class.
- The strongest claim differentiator is performance defined by “total PG esters” impurity ceilings at defined storage conditions, including:
- ≤0.11% at 1 month / 5°C (Claim 1),
- ≤0.12% at 15 days / 25°C (Claim 16),
- plus additional dependent ceilings up to 12 months / 5°C.
- Dependent claims narrow further using:
- antioxidant identity (thioglycerol/monothioglycerol),
- antioxidant concentration band (~2.5 mg/mL to ~35 mg/mL),
- bendamustine concentration ranges (~20–60 mg/mL, with tighter ~25–50 mg/mL, including ~50 mg/mL),
- and stacked stability constraints at 25°C.
- Generic risk is product-specific and analytical: infringement depends on whether the accused liquid’s formulation and measured stability match the claimed PG ester thresholds and solvent/antioxidant selections.
- A complete US patent landscape, Orange Book status, and exclusivity timeline cannot be derived from the claim text alone.
FAQs
1) What exactly is “total PG esters” doing in the claim scope of U.S. 9,572,797?
It functions as the main stability-performance limiter tying infringement to an analytically measured impurity level at specified storage timepoints and temperatures.
2) If a bendamustine liquid uses an antioxidant on the list but at a different concentration, does it avoid the patent?
It may avoid dependent claims that require the antioxidant concentration band, but independent claims still require only a “stabilizing amount,” which can be litigated.
3) Can a product infringe Claim 1 but avoid Claim 16 (or vice versa)?
Yes, in principle, because the independent claims use different impurity/timepoint anchors (1 month/5°C vs 15 days/25°C).
4) Does the patent cover only leukemia, Hodgkin’s disease, and multiple myeloma, or does it also cover other indications?
Based on the provided claim text, it is limited to those three indications.
5) What is the most direct formulation variable for design-around: solvent ratio, antioxidant identity, or PG ester threshold?
The most direct levers are solvent system (PEG:PG ratio and v/v fluid range), antioxidant identity (must be one of the enumerated species), and forcing total PG esters above at least one claimed storage threshold.
References
(1) None provided.
